Rate My Professor Morna Dorsey

Dr. Dorsey's research centers on three key areas: optimizing diagnosis and care for patients with primary immunodeficiency, investigating the psychosocial impact of these conditions on patients and families, and developing treatments for food allergy and eosinophilic disorders. She is principal investigator on the California SCID Consortium Long-term Follow-up Program and co-investigator on NIH-funded projects for rare genetic immune diseases. Her influential publications include 'Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC' (Blood Advances, 2026), 'Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency' (Journal of Clinical Immunology, 2025), 'Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy' (New England Journal of Medicine, 2023), and 'Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening' (Journal of Allergy and Clinical Immunology, 2017). Through her leadership in the Primary Immune Deficiency Treatment Consortium (PIDTC), Dr. Dorsey has advanced newborn screening protocols, improved transplantation outcomes, and enhanced long-term care for immunodeficient children, significantly impacting clinical practice and patient survival rates in the field.